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Angiotensin II infusion increases plasma erythropoietin levels erythropoietin (EPO) levels decreased during ACEI treat-
via an angiotensin II type 1 receptor-dependent pathway. ment [9–11], suggesting a link between angiotensin II
Background. Angiotensin-converting enzyme inhibitors (Ang II) and EPO. Furthermore, infusion with renin(ACEIs) have been shown to lower hematocrit and erythropoi-
substrate in experimental animals has been shown toetin (EPO), but a direct link between angiotensin II (Ang II)
increase EPO concentrations [12]. Because the decreaseand EPO in humans has not been shown.
Methods. Placebo or Ang II was infused for six hours in in EPO concentrations was not statistically significant in
nine healthy male volunteers with and without blockade of the all clinical studies on the use of ACEIs in post-transplant
Ang II subtype 1 receptor (AT1R). EPO concentrations were erythrocytosis [13–15], the influence of Ang II on EPOmeasured 3, 6, 12, and 24 hours after the start of the infusion.
has been questioned [14]. We therefore performed aResults. Ang II raised the mean arterial pressure by about
low-dose Ang II infusion in healthy volunteers with and20 mm Hg. Consistent with the known diurnal variation, EPO
levels rose significantly (P 0.02) during the day in all groups. without a blockade of AT1R to discover whether there
During Ang II infusion, EPO levels rose to significantly higher was a stimulation of EPO production by Ang II and
levels after 6 and 12 hours compared with placebo [9.9 3.5 vs.
whether this could be inhibited by blockade of AT1R.7.2 3.1 mU/mL (3 h, PNS); 16.9 4.5 vs. 8.8 3.7 mU/mL
(6 h, P  0.01); 17.0  8.6 vs. 11.1  4.7 mU/mL (12 h, P 
0.01)] and returned to baseline after 24 hours (7.9  3.8 vs.
METHODS10.6  8.6 mU/mL, P  NS). With AT1R blockade, blood
pressure remained normal during Ang II infusion, and EPO Subjects
levels were never significantly different from placebo [6.8 
After approval of the study protocol by the ethics4.8, 10.5  5.6, 13.1  9.0, and 12.4  10.1 mU/mL at 3, 6, 12,
committee of the J.W. Goethe-Universita¨t (Frankfurt/and 24 h after infusion, respectively, P  NS].
Conclusions. Ang II increases EPO levels in humans. This Main, Germany) and written informed consent, nine
increase requires the participation of AT1R. healthy male volunteers (aged 29  4 years) were stud-
ied. The screening examination included history and
physical examination, 12-lead echocardiogram, complete
A decrease of hematocrit or hemoglobin as a side blood count, serum chemistry, and coagulation. All vol-
effect of antihypertensive treatment with angiotensin- unteers had normal blood pressure and body mass index.
converting enzyme inhibitors (ACEIs) in patients with Blood pressure was monitored every five minutes and
renal disease (patients on hemodialysis and renal trans- later at 30-minute intervals by the oscillometric method
plant patients) has been described by several groups [1–5]. (Bosomat, Jungingen, Germany). Placebo (isotonic sa-
ACEIs therefore have become the standard treatment line) or Ang II (Hypertensin, dissolved in isotonic saline;
for postrenal transplant erythrocytosis (PTE) [6, 7], an Novartis Pharma, Basel, Switzerland) was infused for six
increased production of red blood cells of unknown etiol- hours at a rate of 3 mL/hour. The experiments started
ogy in renal transplant recipients [8]. In most studies, at 7 a.m. Ang II was started at a dose of 1.25 g/min,
and the dose was increased in 0.625 g increments until
systolic blood pressure was approximately 10 mm HgKey words: anemia, ACE inhibition, hematocrit, hypertension, hemo-
dialysis, transplantation, end-stage renal disease. above baseline. The same individual Ang II infusion
schedule was given after pretreatment of the volunteersReceived for publication July 26, 2000
with valsartan (Diovan; Novartis Pharma), 80 mg on theand in revised form January 16, 2001
Accepted for publication February 9, 2001 evening before and 80 mg on the morning four hours
before the study. EPO plasma levels (Quantikine IVD; 2001 by the International Society of Nephrology
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Fig. 2. Erythropoietin (EPO) plasma levels in healthy volunteers fol-
lowing a six-hour placebo or Ang II infusion without and with pretreat-Fig. 1. Mean arterial pressure in healthy volunteers during a six-hour
ment with valsartan, an AT1R blocker. Symbols are: () placebo; ( )placebo or angiotensin II (Ang II) infusion without and with pretreat-
Ang II; ( ) Ang II  valsartan; *P  0.01 vs. placebo. Data arement with valsartan, an Ang II subtype 1 receptor (AT1R) blocker. represented as mean  SEM.Symbols are: () placebo; () Ang II; () Ang II  valsartan; *P 
0.01 vs. placebo. Data are represented as mean  SEM.
Table 1. Hemoglobin and reticulocytes in healthy volunteers before
and 24 hours after placebo or angiotensin II (Ang II) infusion
with and without Ang II subtype 1 receptor (AT1R) blockadeR&D, Minneapolis, MN, USA) were measured 3, 6, 12,
and 24 hours after the start of the infusion. Before and Ang II 
Placebo Ang II valsartan P a24 hours after the start of the infusion, the hemoglobin
Hemoglobin g/dLconcentration and reticulocyte counts were obtained.
at baseline 14.10.28 13.50.23 13.10.26 NSDuring Ang II infusion, one volunteer dropped out after 24 hours 14.20.28 13.80.19 13.90.31
because of headache. One further volunteer did not com- Reticulocytes %
at baseline 11.11.34 9.41.28 10.41.09 NSplete the Ang II infusion after valsartan pretreatment
after 24 hours 8.61.02 10.61.40 11.01.20
because of problems with venous cannulation. Therefore,
a Compared to placebo, determined by paired Wilcoxon test.
the number of subjects was nine for the placebo infusion, Data are represented as mean  SEM.
eight for the Ang II infusion, and seven for the Ang II
infusion following AT1R blockade. Missing values were
not replaced. Since calculation of the statistics using only EPO concentrations returned to normal (Fig. 2). After
the seven volunteers who completed the study did not pretreatment with valsartan EPO levels were never dif-
affect the results, we decided to show the data strictly ferent from placebo following Ang II infusion. Consis-
as they have been obtained. tent with the known diurnal variation of EPO levels,
Data are given as mean SEM. Statistical comparison within-group comparisons showed a statistically signifi-
was by paired Wilcoxon test and multivariate analysis cant (P  0.02) increase of EPO levels over time in the
of variance (ANOVA; SPSS 8.01; SPSS Inc., Chicago, placebo and in the Ang II  valsartan group. Analyzing
the data by multivariate ANOVA, taking into accountIL, USA).
both time and treatment group, confirmed the data by
showing a significant influence of both these variables
RESULTS on EPO concentrations. Hemoglobin concentrations and
reticulocyte counts were not significantly altered byAngiotensin II infusion increased mean arterial blood
Ang II infusion (Table 1).pressure significantly by approximately 20 mm Hg. This
pressure response was completely inhibited by pretreat-
ment with valsartan (Fig. 1), suggesting effective block- DISCUSSION
ade of Ang II receptors. Compared with placebo, EPO The discussion concerning the mechanism by which
levels were significantly higher after six hours of Ang II treatment with an ACEI leads to a decrease in hemato-
infusion and remained significantly elevated at 12 hours. crit remains controversial. Most authors did [9–11], but
some did not [13–15] find a significant decrease of EPOTwenty-four hours after the start of the Ang II infusion,
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levels in patients such treated. In earlier experiments in appears to have an influence on EPO levels in humans.
rats, an increase of EPO levels following infusion of With regard to the hematological side effects of ACEIs
renin substrate and a close correlation between renin and AT1R blockers, an influence of these drugs on the
and EPO levels have been demonstrated [12, 16, 17]. proliferation of hematopoietic cells may also be involved.
In humans, a recently published study showed that the
increase in EPO following controlled hemorrhage could ACKNOWLEDGMENTS
be augmented by infusion of Ang II [18].
Angiotensin II (Hypertensin) and valsartan (Diovan) were kindly
For the treatment of PTE, both ACEIs and AT1R provided by Novartis Pharma. These data were presented in part at
the 1999 Annual Meeting of the American Society of Nephrologyblockers have been used successfully [6, 19]. The patho-
(Miami, FL, USA).physiology of PTE remains unresolved. Some authors
favored increased EPO production by the transplant or Reprint requests to Jan Gossmann, M.D., Funktionsbereich Nephro-
the native kidneys as a reason, whereas others have logie, Med. Klinik IV, Zentrum der Inneren Medizin, Klinikum der
Johann Wolfgang Goethe-Universita¨t, Theodor-Stern-Kai 7, 60590found no evidence for increased EPO levels in patients
Frankfurt/Main, Germany.with PTE [8]. In our opinion, the effectiveness of ACEI
and AT1R blocker treatment does not necessarily imply
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